ŠPUNAROVÁ, Michaela, Jitka MALČÍKOVÁ, Nikola TOM, Marek BORSKÝ, Yvona BRYCHTOVÁ, Michael DOUBEK, Anna PANOVSKÁ, Hana SKUHROVÁ FRANCOVÁ, Kristina ĎURECHOVÁ, A. BRZOBOHATÁ, Anna FREIBERGEROVÁ, Marie JAROŠOVÁ, Marek MRÁZ, Šárka POSPÍŠILOVÁ, Jiří MAYER a Martin TRBUŠEK. Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience. In 23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere. 2018. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1469388, author = {Špunarová, Michaela and Malčíková, Jitka and Tom, Nikola and Borský, Marek and Brychtová, Yvona and Doubek, Michael and Panovská, Anna and Skuhrová Francová, Hana and Ďurechová, Kristina and Brzobohatá, A. and Freibergerová, Anna and Jarošová, Marie and Mráz, Marek and Pospíšilová, Šárka and Mayer, Jiří and Trbušek, Martin}, booktitle = {23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere}, keywords = {patients; CLL; aberrations; chemoimmunotherapy}, language = {eng}, title = {Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience}, year = {2018} }
TY - CONF ID - 1469388 AU - Špunarová, Michaela - Malčíková, Jitka - Tom, Nikola - Borský, Marek - Brychtová, Yvona - Doubek, Michael - Panovská, Anna - Skuhrová Francová, Hana - Ďurechová, Kristina - Brzobohatá, A. - Freibergerová, Anna - Jarošová, Marie - Mráz, Marek - Pospíšilová, Šárka - Mayer, Jiří - Trbušek, Martin PY - 2018 TI - Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience KW - patients KW - CLL KW - aberrations KW - chemoimmunotherapy N2 - Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience, Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience. ER -
ŠPUNAROVÁ, Michaela, Jitka MALČÍKOVÁ, Nikola TOM, Marek BORSKÝ, Yvona BRYCHTOVÁ, Michael DOUBEK, Anna PANOVSKÁ, Hana SKUHROVÁ FRANCOVÁ, Kristina ĎURECHOVÁ, A. BRZOBOHATÁ, Anna FREIBERGEROVÁ, Marie JAROŠOVÁ, Marek MRÁZ, Šárka POSPÍŠILOVÁ, Jiří MAYER a Martin TRBUŠEK. Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience. In \textit{23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere}. 2018.
|